Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists.
about
Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to ClinicToll-like receptor 2 and type 2 diabetes.The Modified JiuWei QiangHuo Decoction Alleviated Severe Lung Injury Induced by H1N1 Influenza Virus by Regulating the NF- κ B Pathway in MiceImmunotherapy using dendritic cells against multiple myeloma: how to improve?Cellular immunotherapy using dendritic cells against multiple myelomaParasite Manipulation of the Invariant Chain and the Peptide Editor H2-DM Affects Major Histocompatibility Complex Class II Antigen Presentation during Toxoplasma gondii Infection.Activation and regulation of interferon-β in immune responses.Type I interferons as regulators of human antigen presenting cell functions.TLR9: an important molecule in the fight against hepatitis B virus.Porcine CD74 is involved in the inflammatory response activated by nuclear factor kappa B during porcine circovirus type 2 (PCV-2) infection.The effect of depression and anxiety on expression levels of toll like receptor signaling molecules in chronic HBV infected patients.A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.Innate Immunity to Campylobacter jejuni in Guillain-Barré Syndrome.Defining the distinct, intrinsic properties of the novel type I interferon, epsilon.Results of a Phase II clinical trial with Id-protein-loaded dendritic cell vaccine in multiple myeloma: encouraging or discouraging?The adapter proteins of TLRs, TRIF and MYD88, are upregulated in depressed individuals.Resolvin D2 Restrains Th1 Immunity and Prevents Alveolar Bone Loss in Murine Periodontitis.High protein intake is associated with low plasma NAD+ levels in a healthy human cohort
P2860
Q27023621-A116831E-9A87-411D-B925-097174646B17Q33634951-EA8F075A-49D6-4524-B908-FAF29DFCD633Q35672351-648A1B27-2EBC-48C0-952B-070DC44ECCD6Q35852574-FBEC9C58-FCEE-4171-9BB7-5D984DDA523EQ35865581-3FC1AEC4-8491-4811-B8F2-BF3E8C5D23BBQ36053611-0F88CF26-ACD8-4CEC-9240-50AC92F72964Q37992879-E45EE78A-C5EA-49BC-A5E5-9C4B80C302C8Q38215320-7D951666-4B2F-47F6-8518-4FB0605BC21DQ38221320-753D53C0-6346-4598-A1AD-95AD537E0FFEQ39143909-943126D2-5AB3-4E47-BA93-0DB7BB724271Q40652277-0890A268-F87D-41A2-B779-205D743FBDD3Q41092396-19A98764-AE90-49A8-AE94-DDBAB820B628Q41199354-2BFFB08B-8700-49E6-9D48-8E90613D7F3DQ46251732-9C0DF9E1-7F7B-4F1A-BD82-156F8C552447Q47562358-B4651440-971B-484B-90CA-7410B03810EEQ48143702-9649231A-7D88-4EC9-8514-4B38F4B4D5C6Q55250059-DF72DD71-6B51-4475-B943-3C4AE40F6203Q58775085-BBEC0DAE-DBE6-45A4-ABBB-93571E763522
P2860
Type I and II interferons enhance dendritic cell maturation and migration capacity by regulating CD38 and CD74 that have synergistic effects with TLR agonists.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Type I and II interferons enha ...... tic effects with TLR agonists.
@en
Type I and II interferons enha ...... tic effects with TLR agonists.
@nl
type
label
Type I and II interferons enha ...... tic effects with TLR agonists.
@en
Type I and II interferons enha ...... tic effects with TLR agonists.
@nl
prefLabel
Type I and II interferons enha ...... tic effects with TLR agonists.
@en
Type I and II interferons enha ...... tic effects with TLR agonists.
@nl
P2093
P2860
P356
P1476
Type I and II interferons enha ...... tic effects with TLR agonists.
@en
P2093
Byoung Chul Park
Cheol Yi Hong
Chun-Ji Jin
Deok-Hwan Yang
Hyeoung-Joon Kim
Hyun Ju Lee
Ik-Joo Chung
Jae-Sook Ahn
Je-Jung Lee
Mi-Seon Lim
P2860
P2888
P304
P356
10.1038/CMI.2011.7
P577
2011-03-21T00:00:00Z